Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Drug Modulators Targeting Gene-Dosage Disease CMT1A

25 Apr 2012

Abstract excerpt

The structural integrity of myelin formed by Schwann cells in the peripheral nervous system (PNS) is required for proper nerve conduction and is dependent on adequate expression of myelin genes including peripheral myelin protein 22 (PMP22). Consequently, excess PMP22 resulting from its genetic duplication and overexpression has been directly associated with the peripheral neuropathy called Charcot-Marie-Tooth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hereditary Neurological Disorders
Share to Nerve injury and regeneration
Share to Peripheral Neuropathies and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22530759
DOI: 10.1021/cb300048d

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Drug Modulators Targeting Gene-Dosage Disease CMT1APMID 22530759Read ↗

CMT1A current gene therapy approaches and promising biomarkersSemantic proximity Read ↗

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease.Semantic proximity Read ↗

Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future PerspectivesSemantic proximity Read ↗

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathySemantic proximity Read ↗

The Current State of Charcot-Marie-Tooth Disease Treatment.Semantic proximity Read ↗

A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A miceSemantic proximity Read ↗

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumorsSemantic proximity Read ↗

A Computational Approach to Identify a Potential Alternative Drug With Its Positive Impact Toward PMP22.Semantic proximity Read ↗

PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent modelsSemantic proximity Read ↗

Study of an RNA-Focused DNA-Encoded Library Informs Design of a Degrader of a r(CUG) Repeat ExpansionSemantic proximity Read ↗

Prioritizing Combinational Drug Screening: A Ranking System for <i>In Vitro</i> Drug Combinations in Neurofibromatosis Type 1Semantic proximity Read ↗

Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.